Perez-Nieves Magaly, Ivanova Jasmina I, Hadjiyianni Irene, Zhao Chen, Cao Dachuang, Schmerold Luke, Kalirai Samaneh, King Sarah, DeLozier Amy M, Birnbaum Howard G, Peyrot Mark
a Eli Lilly and Company , Indianapolis , IN , USA.
b Analysis Group Inc. , New York , NY , USA.
Curr Med Res Opin. 2017 Oct;33(10):1833-1842. doi: 10.1080/03007995.2017.1341403. Epub 2017 Jul 7.
People with type 2 diabetes mellitus (T2DM) often interrupt basal insulin treatment soon after initiation. This study aimed to describe the experiences during and after basal insulin initiation among people with T2DM with different persistence patterns.
Adults with T2DM from France, Germany, Spain, UK, US, Brazil, and Japan were identified from consumer panels for an online survey. Respondents who initiated basal insulin 3-24 months prior to survey date were categorized as continuers (no gaps of ≥7 days in insulin treatment); interrupters (first gap ≥7 days within 6 months of initiation and restarted insulin); and discontinuers (stopped insulin for ≥7 days within 6 months of initiation without restarting).
Among 942 participants, continuers were older than interrupters and discontinuers (46, 37, and 38 years, respectively, p < .01). Continuers reported having fewer concerns before and after insulin initiation than interrupters and discontinuers, while interrupters had the most concerns. Continuers also reported fewer challenges during the first week of insulin use. Continuers were more likely to respond that insulin use had a positive impact on specific aspects of life than interrupters and discontinuers, for example on glycemic control (73.0%, 63.0%, and 61.8%, respectively; p < .01 vs. continuers).
Among people with T2DM with different persistence patterns after basal insulin initiation there were significant differences in patient characteristics and experience during and after insulin initiation. Interrupters and discontinuers more frequently reported having concerns and challenges during the initiation process, negative impacts after initiation, and less improvement in glycemic control than continuers.
2型糖尿病(T2DM)患者在开始基础胰岛素治疗后不久常常中断治疗。本研究旨在描述不同持续治疗模式的T2DM患者在基础胰岛素起始治疗期间及之后的经历。
从法国、德国、西班牙、英国、美国、巴西和日本的消费者小组中识别出成年T2DM患者进行在线调查。在调查日期前3 - 24个月开始基础胰岛素治疗的受访者被分为持续使用者(胰岛素治疗无≥7天的中断);中断使用者(起始治疗6个月内首次出现≥7天的中断且重新开始胰岛素治疗);以及停止使用者(起始治疗6个月内停止胰岛素治疗≥7天且未重新开始)。
在942名参与者中,持续使用者比中断使用者和停止使用者年龄更大(分别为46岁、37岁和38岁,p <.01)。持续使用者报告在胰岛素起始治疗前后的担忧比中断使用者和停止使用者更少,而中断使用者的担忧最多。持续使用者在胰岛素使用的第一周也报告了较少的挑战。与中断使用者和停止使用者相比,持续使用者更有可能回应称胰岛素使用对生活的特定方面有积极影响,例如血糖控制(分别为73.0%、63.0%和61.8%;与持续使用者相比,p <.01)。
在基础胰岛素起始治疗后具有不同持续治疗模式的T2DM患者中,胰岛素起始治疗期间及之后的患者特征和经历存在显著差异。与持续使用者相比,中断使用者和停止使用者更频繁地报告在起始治疗过程中有担忧和挑战、起始治疗后有负面影响以及血糖控制改善较少。